Tags Archive Navigation
icon
-
Media ReleaseAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
-
Media ReleaseAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
-
Media ReleaseFDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis stellt neue Leiterin der Pharmaceuticals Business Unit vor
-
Media ReleaseNovartis announces new leader of Pharmaceuticals Business Unit
-
Media ReleaseNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
-
Media ReleaseNovartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
-
Media ReleaseNovartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
-
Media ReleaseNovartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
-
Media ReleaseNovartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
-
Media ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
-
Media ReleaseNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Pagination
- ‹ Previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- …
- 16
- › Next page